AccueilWXIBF • OTCMKTS
add
WuXi Biologics (Cayman) Inc
Dernière clôture
2,50 $
Plage sur l'année
1,30 $ - 6,60 $
Capitalisation boursière
70,05 Md HKD
Volume moyen
311,00
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
HKG
Actualités des marchés
L'Usine Nouvelle
il y a 14 heures
Wall Street en ordre dispersé, le Nasdaq en hausse grâce à la "tech"
0,013 %
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (CNY) | juin 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 4,29 Md | 0,97 % |
Charges d'exploitation | 765,14 M | 21,62 % |
Résultat net | 749,54 M | -33,86 % |
Marge bénéficiaire nette | 17,48 | -34,51 % |
Bénéfice par action | — | — |
EBITDA | 1,24 Md | -13,32 % |
Taux d'imposition effectif | 11,36 % | — |
Bilan
Total des actifs
Total du passif
| (CNY) | juin 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 9,53 Md | 9,60 % |
Total des actifs | 56,11 Md | 7,60 % |
Total du passif | 11,46 Md | -12,46 % |
Total des capitaux propres | 44,64 Md | — |
Actions en circulation | 4,15 Md | — |
Ratio cours/valeur comptable | 0,26 | — |
Rentabilité des actifs | 4,05 % | — |
Retour sur capitaux | 4,62 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (CNY) | juin 2024info | Variation Y/Y |
|---|---|---|
Résultat net | 749,54 M | -33,86 % |
Trésorerie (opérations) | 651,06 M | -52,65 % |
Trésorerie (invest.) | -191,26 M | 75,93 % |
Trésorerie (financement) | -737,79 M | -684,70 % |
Variation nette en trésorerie | -258,16 M | -153,79 % |
Flux de trésorerie dispo. | 350,65 M | 52,56 % |
À propos
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Date de fondation
2010
Site Web
Employés
12 435
